Compass Pathways PLC 8-K filings

Compass Pathways reports strong Q2 2026 results with its COMP360 psilocybin therapy showing significant progress towards regulatory approval and a robust cash reserve extending into 2028.

Compass Pathways announced positive 26-week results from its Phase 3 COMP006 trial for COMP360 in treatment-resistant depression, showing rapid onset and durable efficacy.

COMPASS Pathways shareholders re-elected board members and approved executive compensation at the 2026 Annual General Meeting.

Compass Pathways reported strong Q1 2026 results, highlighted by FDA granting rolling submission for COMP360 and a significant increase in cash reserves.

Compass Pathways announced its full-year 2025 financial results and significant progress in its COMP360 clinical programs for TRD and PTSD, extending its cash runway into 2028.

COMPASS Pathways plc announced the pricing of a public offering totaling $150.0 million, including ADSs and pre-funded warrants, to fund its clinical trials and operations.

Compass Pathways plc announced highly statistically significant positive topline results from its second pivotal Phase 3 COMP006 trial for COMP360 psilocybin in treatment-resistant depression, alongside consistent safety data.

COMPASS Pathways PLC has amended its loan agreement with Hercules Capital, Inc., securing up to $150 million in new debt financing tied to clinical, regulatory, and commercial milestones.

Compass Pathways announced accelerated commercial launch plans for COMP360 in Treatment Resistant Depression by 9-12 months, despite a widened net loss in Q3 2025 primarily due to warrant liability adjustments.

COMPASS Pathways strengthens its Board of Directors with the appointment of Dr. Jeffrey Jonas, a seasoned neuroscience expert, while Thomas Lnngren retires.

COMPASS Pathways announced positive primary endpoint results from its first COMP360 Phase 3 trial for treatment-resistant depression, alongside a strong cash position extending its runway into 2027.

COMPASS PATHWAYS PLC announced the appointment of Justin Gover, former CEO of GW Pharmaceuticals, to its Board of Directors, effective July 29, 2025, while Dr. Linda McGoldrick will retire from the Board on October 31, 2025.

COMPASS PATHWAYS PLC announced the successful achievement of the primary endpoint in its Phase 3 COMP005 trial for treatment-resistant depression, demonstrating a highly statistically significant reduction in symptom severity with its COMP360 psilocybin formulation.

COMPASS PATHWAYS PLC announced that all proposals presented at its 2025 Annual General Meeting of Shareholders on June 12, 2025, were approved, including the re-election of four directors, the re-appointment of auditors, and the authorization for directors to allot shares.

Compass Pathways announces its Q1 2025 financial results, highlighting progress in its Phase 3 clinical trials for COMP360 psilocybin treatment in treatment-resistant depression (TRD) and a solid cash position.

Compass Pathways has appointed PricewaterhouseCoopers LLP, United States (PwC US) as its independent registered public accounting firm, replacing PricewaterhouseCoopers LLP, United Kingdom (PwC UK), effective upon completion of PwC UK's review of the interim period ended March 31, 2025.

Compass Pathways announces its Q4 and full-year 2024 financial results, highlighting progress in its Phase 3 trials for treatment-resistant depression (TRD) and plans for a late-stage clinical program in post-traumatic stress disorder (PTSD).

Compass Pathways has announced the pricing of a $150 million underwritten public offering of American Depositary Shares (ADSs) and warrants, with potential proceeds reaching $353 million if warrants are fully exercised.

Compass Pathways is prioritizing its COMP360 program, leading to a workforce reduction and revised timelines for clinical trial data releases.

Compass Pathways announced the appointment of Gino Santini as Chairman, Lori Englebert as Chief Commercial Officer, and reported its second quarter 2024 financial results, including a net loss of $38.1 million.

COMPASS Pathways held its 2024 Annual General Meeting, where shareholders voted on key proposals including the re-election of directors and the appointment of auditors.

Compass Pathways announced its first quarter 2024 financial results, highlighted by progress in its Phase 3 trial for treatment-resistant depression and positive Phase 2 data in post-traumatic stress disorder.

Compass Pathways reported positive top-line results from a phase 2 study of COMP360 psilocybin treatment for PTSD, showing significant symptom improvement and good tolerability.

Compass Pathways announces the resignation of co-founders George Goldsmith and Ekaterina Malievskaia from the board of directors, with David Norton stepping in as interim chair.

Compass Pathways announced its fourth quarter 2023 financial results, provided updates on its clinical trials, and appointed a new Chief Financial Officer.